medication: with the development of multinational pharmaceutical companies, biomedicine, the internet and new epidemics, the terms have undergone a shift of meaning (Terraneo, Sarti and Tognetti Bordogna 2014; Sironi and Tognetti Bordogna 2009 ). An ever more imposing array of drugs are being prescribed by doctors to contain and control all new forms of pathology and social problems (Zola 1972; Illich 1976) , giving rise to a process now known as the medicalisation of society (Conrad, Gabe and Williams 1992) .
In addition to the above factors, we are now witnessing the rise of citizen expertise about the diseases of society, and the resort to drugs in order to enhance social performance, relating, and the response to challenge, rather than in response to illness as such. This process has been dubbed the pharmaceuticalisation of society (Williams, Gabe and Davis 2008) . It consists in the use of drugs or medication to improve individual performance, without consulting a doctor.
While the medicalisation process has now taken theoretical root in the sociology of health, there is much less familiarity with the attendant concepts of biomedicalisation and pharmaceuticalisation. In this paper we shall be discussing pharmaceuticalisation and how sociology may help understand and explain the phenomenon. We shall be looking at AngloSaxon sociology in particular, for its description of the pharmaceuticalisation process and how it is spreading.
From medicalisation to pharmaceuticalisation
Conrad was one of the first scholars to define the concept of medicalisation (Conrad 1992; Conrad and Schneider 1992) and describe its impact (Conrad 2007) . He sees it as a process by which problems lying outside medicine begin to be treated and defined as medical. He points out that over the last thirty years there has been an increase in 'living issues' being turned into disorders, syndromes connected with behaviour, psychic states or physical conditions. The author wonders whether this is a new epidemic or a new 121 ability on the part of medicine to deal with pre-existing issues. Or do we now find medicine diagnosing a range of issues as problems subject to medical treatment, even though there is little clear evidence that they are medical in nature (Conrad 2007) . In the name of clarifying the process of medicalisation, Conrad and other authors (Rodeschini 2012) have mounted studies to explore the social basis for this expanding jurisdiction of medicine which forms one of the most powerful late-twentieth-century transformations in the West (Clarke et al. 2003) . The 1980s marked the turning point in the medicalisation process, with not only physicians occupying centre-stage in the analysis, but patients, the pharmaceutical industry, the media and the State.
To Conrad (2007 Conrad ( , 2009 , along with biotechnology and managed care, one of the main factors changing the key mechanisms of medicalisation has been the transformation of patients into consumers. Conrad (2007) also points out the leading part played by technology in the medical process, spurred by the pharmaceutical industry and the manufacturers of biotechnology.
Certain authors in the nineties talked of a process of de-medicalisation. Moynihan and Smith (2002) saw the new information and communication technology as a potent tool for de-medicalisation, since it tends to make the patient more responsible. With the capillary spread of information, people have become more aware of the cost-benefit of medicalising their lives.
Others (Ballard and Elston 2005) argue that medicalisation is becoming more and more two-way and multi-dimensional. To listen to Conrad and Schneider (1992) , medicalisation is part and parcel of modernity. Elston et al. (2002) wonder whether we are witnessing a historical turning-point towards a post-modern era; that more medicalisation may well be in store.
We note the beginning of a trend among scholars, to whom medicalisation is no longer a sufficient interpretive category to account for the ever more complex medical and social phenomena. Though medicalisation has remained a key concept in the sociology of health, increasingly we see it being challenged, its boundaries stretched to cover a 122 techno-scientific era of biomedicalisation (Clarke et al. 2003) , while there is increasing recognition of the part being played by the pharmaceutical industry in this process Gabe 2011a, 2011b) .
The much-debated change in progress within medicine is well illustrated by the works of Clarke et al. (2003 ). Clarke focuses on technology spurring medicalisation; she points out the limitations of classical medicalisation theory and suggests it should be broadened into 'biomedicalisation'. argue that medicalisation no longer explains the full picture emerging from their research and claim that biomedicalisation, taking its cue from medicalisation, shifts the emphasis onto the scope for techno-scientific intervention, (re)organization and transformation.
Picking up from Latour, the two authors suggest that the term 'technoscience' covers the need to see technology and science as 'co-constitutive' ); they deny the existence of 'pure forms' of scientific research or technology divorced from practical application.
'Techno-science' lends itself, again, to new kinds of intervention, in sickness and in health, in treatment and in the organization of medical therapy, as well as in the way we frame and lead our lives. If medicalisation (Conrad 2007 ) is about controlling and normalizing human functioning, biomedicalisation (Coveney, Gabe and Williams 2012) focuses on changes in medicine and on the human body: not just to cure, but to personalize, enhance and optimize health. Biomedicine and its tools are of use not just to pathology, but in ensuring better health in future ).
Today this theoretical framework (medicalisation and biomedicalisation) is itself being questioned by some scholars. Is it sufficient to explain the massive and increasing development and use of drugs, and the ever more powerful role of the pharmaceutical industry, not just in producing and selling, but also in validating their wares (Metzl and Herzig 2007) .
Various authors (Abraham 2009 (Abraham , 2010 Bell and Figert 2012) have pointed out that social scientists have long studied drugs and the drug industry, but in relation to increasing consumption of the product (Busfield 2006) , or in relation to the role drugs have in medicalising society (Williams et al. 2008a) . Such authors have seen the crucial step to be recognition of the growing importance of the pharmaceutical industry in medicalisation . In Conrad's view (2007) 
Pharmaceuticalisation of life and society
The process of pharmaceuticalisation is found in milieus that are we broaden the diagnostic criteria, that may bring about both medicalisation and the discovery of sufferers who were previously undetected. Another weakness of the biomedicalist argument is that pharmaceuticalisation is spurred not so much by scientific discoveries responding to new medical needs, but by an increase in promotion and marketing.
Marketing is a side to the pharmaceutical sector that has grown greatly. Medical experts have been brought into marketing strategy and involved in developing products. Pharmaceutical companies fund meetings 127 and symposia, and also magazines and magazine articles that speak well of certain drugs. They hire public relations consultants to get the mass media to hype a product, or to block or hold back certain news items.
The key feature of the consumer market is the knowledgeableness of consumers and consumer associations. Abraham (2010) They ended by calling for a framework within which to cover the full complexity and global aspects of the problem. This especially meant paying attention to resistance and ambivalence, the constant role of the doctor-drug link, the crisis of innovation in industry and the contribution of research both in the North and in the South.
Conclusions
We have discussed the need to move beyond and extend the notion of medicalisation and embrace that of pharmaceuticalisation which better fits the new phenomena of consumption, production and marketing of drugs.
We are witnessing a new theoretical and analytical dimension, and pharmaceuticalisation still has points of definition and theory that need clarifying and consolidating, however much Williams may regard it as a fully-formed social and scientific concept . The phenomenon proves to hinge on the role of drug production and marketing.
We went on to show how in the Anglo-Saxon debate the notions of medicalisation and pharmaceuticalisation are not always mutually exclusive, but frequently highlight different features. In analysing the debate in progress, we find that our present society contains at one and the same time phenomena of pharmaceuticalisation and of de-pharmaceuticalisation, as well as pharmaceuticalisation of public life.
We have taken our cue from the arguments of the main theoreticians of this subject, and gone on to analyse from differing perspectives the various sociological dimensions upon which the concept of pharmaceuticalisation rests.
Lastly, our article has shown how the phenomenon of pharmaceuticalisation is important to understand the pattern of medicament consumption in our society, and also the roles of the various actors in the health, wellness and illness settings, not forgetting individuals' concern with their own performance. This enables the analysis to cover the role of actors on the micro plane (the individual), the middle plane (the relation between individuals and their doctor, the degree of performance society expects of them, and the pharmaceutical companies) and the macro plane (globalization of our drug-conscious society and public health policies of deregulation or pharmaceuticalisation).
Limits and future prospects
This paper does not claim to be exhaustive or generalizable: it is mainly a survey of the literature and the debate over theory, and is hence not backed up by systematic research findings. It also focuses largely on the AngloSaxon literature. While aware of these limitations, we feel it may nonetheless provide a useful summary of the debate and a starting point for investigation of the phenomenon, whether in Anglo-Saxon countries or the rest of the world, and especially in the BRICS countries. In future we believe that studying the process of pharmaceuticalisation and depharmaceuticalisation will assume increasing importance in the sociology of health. Via such studies we will be able to analyse the various new forms of
